

## Paxman publishes newsletter on the approval of an upcoming study with the company's scalp cooling system in South Korea

**Today, Paxman publishes the October issue of its newsletter aimed at shareholders, investors and other interested parties.**

This issue highlights the South Korean Ministry of Food and Drug Safety (MFDS) approval of a trial with Paxman's PSCS system in South Korea to evaluate its effectiveness in reducing permanent chemotherapy-induced alopecia in woman with breast cancer. The trial will begin to recruit patients in November 2020.

The newsletter also includes information on several new system orders and installs in the United States and the Netherlands, the growing US foundation support for Paxman's scalp cooling and the company's busy virtual event schedule for the fourth quarter of 2020.

To read the newsletter and subscribe for upcoming issues, follow this link:

<http://bit.ly/paxoct20en>

PAXMAN's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on PAXMAN's website for investors, [www.paxman.se](http://www.paxman.se). The company encourages feedback and requests on topics for upcoming issues of the newsletter.

### Contacts

Richard Paxman, CEO  
Tel: +44 7968 020641  
Email: [richard@paxmanscalpcooling.com](mailto:richard@paxmanscalpcooling.com)  
[www.paxman.se](http://www.paxman.se)

---

## About Us

---

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via [info@fnca.se](mailto:info@fnca.se) and +46 (0)8 528 003 99.

## Attachments

---

[Paxman publishes newsletter on the approval of an upcoming study with the company's scalp cooling system in South Korea](#)